NO2011012I1 - Cimicoxib; 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salter derav - Google Patents

Cimicoxib; 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salter derav

Info

Publication number
NO2011012I1
NO2011012I1 NO2011012C NO2011012C NO2011012I1 NO 2011012 I1 NO2011012 I1 NO 2011012I1 NO 2011012 C NO2011012 C NO 2011012C NO 2011012 C NO2011012 C NO 2011012C NO 2011012 I1 NO2011012 I1 NO 2011012I1
Authority
NO
Norway
Prior art keywords
cimicoxib
benzenesulfonamide
imidazol
methoxyphenyl
fluoro
Prior art date
Application number
NO2011012C
Other languages
English (en)
Other versions
NO2011012I2 (no
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of NO2011012I1 publication Critical patent/NO2011012I1/no
Publication of NO2011012I2 publication Critical patent/NO2011012I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
NO2011012C 1998-10-16 2011-07-27 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salterderav NO2011012I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9802222 1998-10-16
PCT/ES1999/000327 WO2000023426A1 (es) 1998-10-16 1999-10-15 Nuevos imidazoles con actividad antiinflamatoria

Publications (2)

Publication Number Publication Date
NO2011012I1 true NO2011012I1 (no) 2011-08-08
NO2011012I2 NO2011012I2 (no) 2013-05-06

Family

ID=8305557

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20011790A NO319074B1 (no) 1998-10-16 2001-04-09 Nye imidazoler med anti-inflammatorisk aktivitet, anvendelse derav og farmasoytisk preparat inneholdende disse
NO2011012C NO2011012I2 (no) 1998-10-16 2011-07-27 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salterderav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20011790A NO319074B1 (no) 1998-10-16 2001-04-09 Nye imidazoler med anti-inflammatorisk aktivitet, anvendelse derav og farmasoytisk preparat inneholdende disse

Country Status (20)

Country Link
US (1) US6838476B1 (no)
EP (1) EP1122243B1 (no)
JP (1) JP4480894B2 (no)
KR (2) KR100715918B1 (no)
AR (1) AR024222A1 (no)
AT (1) ATE275549T1 (no)
AU (1) AU6204899A (no)
BE (1) BE2011C024I2 (no)
BR (2) BRPI9914571B8 (no)
CA (1) CA2346847C (no)
CY (1) CY2011009I2 (no)
DE (2) DE69920028T2 (no)
DK (1) DK1122243T3 (no)
ES (1) ES2228109T3 (no)
FR (1) FR11C0028I2 (no)
HK (1) HK1039331B (no)
LU (1) LU91849I2 (no)
NO (2) NO319074B1 (no)
PT (1) PT1122243E (no)
WO (1) WO2000023426A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159489B1 (es) * 2000-03-23 2002-04-16 Uriach & Cia Sa J Nuevos derivados de imidazol con actividad antiinflamatoria.
ES2166710B1 (es) * 2000-04-25 2004-10-16 J. URIACH & CIA, S.A. Nuevos compuestos heterociclicos con actividad antiinflamatoria.
ES2184633B1 (es) 2001-08-07 2004-08-01 J. URIACH & CIA, S.A. Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
BR0309305A (pt) * 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
KR100804827B1 (ko) * 2002-05-17 2008-02-20 씨제이제일제당 (주) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
CA2493458A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
ES2215474B1 (es) * 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
GB0806745D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel imidazole derivatives
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
US20110045101A1 (en) * 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles
CN102464652B (zh) * 2010-11-02 2013-08-28 北京欧博方医药科技有限公司 咪唑衍生物、制备方法及用途
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
IT1168008B (it) * 1981-07-31 1987-05-20 Zambon Spa Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono
US4576958A (en) * 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.

Also Published As

Publication number Publication date
DE69920028T2 (de) 2005-09-22
CY2011009I1 (el) 2014-04-09
NO2011012I2 (no) 2013-05-06
PT1122243E (pt) 2004-12-31
KR100808433B1 (ko) 2008-03-03
EP1122243B1 (en) 2004-09-08
FR11C0028I1 (no) 2011-09-23
DK1122243T3 (da) 2005-01-10
BE2011C024I2 (no) 2019-03-05
BRPI9914571B8 (pt) 2021-07-06
JP4480894B2 (ja) 2010-06-16
KR20060129102A (ko) 2006-12-14
ATE275549T1 (de) 2004-09-15
AR024222A1 (es) 2002-09-25
NO20011790L (no) 2001-06-14
HK1039331B (zh) 2005-01-07
WO2000023426A1 (es) 2000-04-27
CA2346847A1 (en) 2000-04-27
AU6204899A (en) 2000-05-08
US6838476B1 (en) 2005-01-04
NO319074B1 (no) 2005-06-13
LU91849I2 (fr) 2011-09-27
NO20011790D0 (no) 2001-04-09
BRPI9914571B1 (pt) 2011-10-18
KR20010080186A (ko) 2001-08-22
CA2346847C (en) 2009-12-22
BRPI9914571A (pt) 2001-11-06
CY2011009I2 (el) 2014-04-09
KR100715918B1 (ko) 2007-05-08
ES2228109T3 (es) 2005-04-01
EP1122243A1 (en) 2001-08-08
FR11C0028I2 (fr) 2012-06-22
HK1039331A1 (en) 2002-04-19
DE122011100028I1 (de) 2011-12-08
DE69920028D1 (de) 2004-10-14
JP2002527508A (ja) 2002-08-27
BR9914571A (pt) 2001-11-06

Similar Documents

Publication Publication Date Title
NO2011012I1 (no) Cimicoxib; 4[4-klor-5(3-fluor-4-metoksyfenyl)imidazol-1-yl]benzensulfonamid og farmasøytisk aksepterbare salter derav
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
NO2005007I1 (no) Pemetrexed og farmasoytisk akseptable salter derav
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
HUS1300054I1 (hu) Herbicid hatású 3-hidroxi-4-aril-5-oxo-pirazolin-származékok és alkalmazásuk
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
NO2006004I2 (no) Erlotinib hydroklorid og farmasøytisk akseptable salter derav
HK1048306B (zh) 藥學活性磺酰胺衍生物
FR2787313B1 (fr) Implant d'osteosynthese
AU3793501A (en) Generation and management of customer pin's
PT1140835E (pt) Derivados da 3,3-biarilpiperidina e 2,2-biarilmorfolina
AU1743300A (en) Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof
EP1123920A4 (en) HYDRAZINO-OXOACETAMIDE DERIVATIVES AND INSECTICIDES
AU3238701A (en) System for organizing and operating "gye" on network
NO20010405L (no) Pyrazolderivater og salter derav
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
HUP9900064A3 (en) Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof
AU3853097A (en) Benzimidazole derivatives, preparation thereof, and therapeutical uses thereof
ATE243218T1 (de) 2''-deoxyhygromycinderivate
FR2738737B1 (fr) Piton d'ancrage utilisable en chirurgie
AU2028600A (en) Opacifying agent comprising crosslinked caseinate
AU4916699A (en) 4-phenyl- and 4,5-diphenylimidazole derivatives, preparation and therapeutic application
AU5005099A (en) Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
AU6924198A (en) Benzenesulphonamide derivatives, preparation and application thereof in therapy
AU5102698A (en) Physiologically acceptable aqueous solutions and methods for their use